GeneCentric Therapeutics, Inc.

GeneCentric Therapeutics is applying our proprietary rT(I)ME Explorer Platform to identify high resolution molecular subtypes and drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our approach applies our rT(I)ME Explorer Platform to parse the complexity of the tumor and the immune microenvironment and overall tumor biology to generate response signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers, or predictive response signatures, for immune-based, targeted and other cancer therapeutics. In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we can deploy the rT(I)ME Explorer Platform at all stages of the drug development cycle.